Latest From SkelRegen LLC
New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.
Brief profiles of these recently formed companies: ABK Biomedical, LuxCath, Quantamerix, SkelRegen, Thesan Pharmaceuticals, and Ziarco Pharma.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- SkelRegen LLC
- Senior Management
- Scott D Boden, MD, Chief Medical & Technology Office
- Contact Info
Phone: (610) 314-3938
929 South High St.
West Chester, PA 19382
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.